Results 221 to 230 of about 252,843 (247)

The use of concomitant radiotherapy and an attenuated herpes simplex-1 virus improves survival, in intracranial glioblastoma multiforme tumors (astro research fellowship)

, 1998
Jeffrey D. Bradley, Sunil J. Advani, Su-Mi Chung, G. Yancey Gillespie, Jaines Markert, Richard J. Whitley, Bernard Roizman, Ralph R. Weichselbaum   +7 more
openalex   +1 more source

Next Generation Modeling of Glioblastoma Progression: Diffusing Through Time and Brain

Annalen der Physik, EarlyView.
Glioblastoma (GBM) is a fatal brain tumor that will inevitably recur following surgical resection. Early mathematical tumor growth models used the reaction‐diffusion equation to describe the proliferation and invasion of tumor spread. However, with increasingly advanced neuroimaging technology, diffusion tensor imaging data has more recently been ...
Francesca M. Cozzi, Yizhou Wan, Swati Jain, Curtis Holliman, Roxanne C. Mayrand, Stephen J. Price   +5 more
wiley   +1 more source

Recurrence patterns and clinical outcomes in adult cerebellar glioblastoma. [PDF]

Acta Neurochir (Wien)
Oki S, Yamaguchi S, Ishi Y, Motegi H, Gekka M, Tanei ZI, Kanno-Okada H, Takakuwa E, Tanaka S, Mori T, Nishioka K, Aoyama H, Tanaka S, Fujimura M.   +13 more
europepmc   +1 more source

Purinergic P2X receptor 7 (P2X7R) inhibition induced cytotoxicity in glioblastoma. [PDF]

PLoS One
Drill M, Kan LK, Sequeira RP, Jayakrishnan PC, Hunn M, Jones NC, O'Brien TJ, Monif M.   +7 more
europepmc   +1 more source

Publisher's Note: The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: A systematic review. [PDF]

Neurooncol Adv
europepmc   +1 more source

Rat Glioma 101.8 Tissue Strain: Molecular and Morphological Features. [PDF]

Int J Mol Sci
Alekseeva AI, Sentyabreva AV, Kudelkina VV, Miroshnichenko EA, Ikonnikov AV, Kopantseva EE, Kosyreva AM, Fatkhudinov TK.   +7 more
europepmc   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Flow cytometry protocol for cell death analysis in glioblastoma organoids: A technical note. [PDF]

PLoS One
Potthoff AL, Hsieh MC, Melhem A, Ng SS, Pregler BEF, Vieregge A, Raspe M, Friker LL, Zeyen T, Layer JP, Dolf A, Toma MI, Waha A, Pietsch T, Westhoff MA, Vatter H, Hölzel M, Herrlinger U, Schneider M.   +18 more
europepmc   +1 more source

Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Casdatifan is an orally bioavailable small‐molecule hypoxia‐inducible factor‐2α (HIF‐2α) inhibitor currently in development for treating patients with clear cell renal cell carcinomas. The aim of this study was to characterize the pharmacokinetics (PK), pharmacodynamics and safety of casdatifan in healthy participants.
Mohammad Ghasemi, Ji Yun Kim, Lisa Seitz, Lixia Jin, Paul G. Foster, Kai H. Liao, Tzuling Cheng, Elaine Paterson, Maria Velinova, Nicole Rivera Rosario, Reza Khosravan, Balaji Agoram   +11 more
wiley   +1 more source